Evgen Pharma Plc (LON:EVG) CEO Dr Stephen Franklin discusses the broccoli angle, the events surrounding last years IPO and the successful IPO last month.
Evgen Pharma Plc is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. It is also carrying out preclinical work in multiple sclerosis and has a clinical interest in prostate cancer. The Company’s core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin. Evgen Pharma commenced operations in January 2008 and is based in Liverpool, UK, at the Liverpool Science Park. Admission and trading of its Ordinary Shares commenced trading at 8.00 a.m. 21 October 2015 on the AIM market of the London Stock Exchange, £7.0 million before expenses had been raised on behalf of the Company via an oversubscribed Placing of 18,918,919 Ordinary Shares at a price of 37 pence per share with institutional and other investors.